Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
J Eur Acad Dermatol Venereol ; 20(3): 293-8, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16503890

ABSTRACT

There is currently substantial clinical interest in growth hormone (GH) as a protective agent against radiation-related normal tissue injury. To further assess the potential radiation injury-preventive effects of GH, these effects were studied in rats by using a radiation-induced skin injury model. Group 1 received neither GH nor irradiation (control group). Group 2 received 30 Gy of gamma irradiation as a single dose to the right hind legs of the rats (radiation group). Group 3 and 4 received the same irradiation plus either 0.01 U/kg/day GH (RT + 0.01 GH group) or 0.02 U/kg/day GH (RT + 0.02 GH group) subcutaneously. Clinically and histopathologically, acute skin reactions were assessed by two independent experts in radiation oncology and pathology, respectively. Irradiation increased dermatitis in rats when compared with the control group. The severity of radiodermatitis in the rats in the RT + 0.01 GH and RT + 0.02 GH groups was significantly lower than that in the RT group; radiodermatitis developed earlier in the RT group than in the other groups. GH was efficacious in preventing epidermal atrophy, dermal degeneration such as oedema and collagen fibre loss, and hair follicle atrophy, but not better than in the control group. These results are preliminary to studies that will be performed with higher doses of GH in radiation-treated cancer patients, with the aim of reducing radiation-induced toxicity.


Subject(s)
Growth Hormone/administration & dosage , Radiation Injuries, Experimental/prevention & control , Radiation-Protective Agents/administration & dosage , Radiodermatitis/prevention & control , Animals , Disease Models, Animal , Gamma Rays/adverse effects , Injections, Subcutaneous , Male , Radiation Dosage , Radiation Injuries, Experimental/etiology , Radiation Injuries, Experimental/pathology , Radiodermatitis/etiology , Radiodermatitis/pathology , Rats , Rats, Sprague-Dawley , Skin/pathology , Skin/radiation effects
2.
Int J Clin Pract ; 58(7): 662-8, 2004 Jul.
Article in English | MEDLINE | ID: mdl-15311722

ABSTRACT

The purpose was to determine the effects of oral zinc sulphate along with radiotherapy on anti-oxidant enzyme activities in patients with head and neck cancer. Thirty patients with head and neck cancer were randomly assigned to receive either zinc sulphate capsules (including 50 mg zinc) (n = 15) or placebo (n = 15) three times a day, starting on the day of the first radiotherapy fraction and continuing throughout the scheduled radiotherapy course including weekends and 6 weeks after radiotherapy. The patients were treated with telecobalt radiation at conventional fractionation of 2 Gy/fraction and five fractions/ week in 20-35 fractions for a period of 4-7 weeks. Blood samples for biochemical parameters were collected after an overnight fast (12 h) before radiotherapy, the first day and 6 weeks after radiotherapy. In the placebo group, three patients were excluded. No difference was detected in any final measurement activities of erythrocyte anti-oxidant enzyme such as copper-zinc superoxide dismutase (Cu-Zn SOD), catalase (CAT) and glutathione peroxidase (GSH-Px) in the direct comparison between the zinc sulphate and the placebo group, except erythrocyte SOD activities measured the first day after radiotherapy (p < 0.03). In the respective measurement analysis of the groups in themselves, in the zinc sulphate group, while the statistical analysis for the activities of erythrocyte CAT and GSH-Px were significantly different (chi2 = 12.4, p < 0.05; chi2 = 8.9, p < 0.05, respectively) before radiotherapy, the first day and 6 weeks after radiotherapy, the activities of SOD did not differ (chi2 = 4.2, p > 0.05). In these three measurements, there was no statistical significance in the activities of enzymes in erythrocyte Cu-Zn SOD, CAT and GSH-Px in the placebo group. Before radiotherapy, plasma zinc levels were normal in 16 patients (59.2%) and were lower in 11 patients (40.8%) compared with laboratory levels. It would be worthwhile studying the effect of oral zinc sulphate supplements to improve the anti-oxidant enzyme activity in radiation-treated cancer patients, in the hope of reducing radiation-induced toxicity.


Subject(s)
Antioxidants/radiation effects , Head and Neck Neoplasms/radiotherapy , Radiation Injuries/prevention & control , Zinc Sulfate/therapeutic use , Administration, Oral , Adult , Aged , Catalase/metabolism , Combined Modality Therapy , Female , Glutathione Peroxidase/metabolism , Head and Neck Neoplasms/enzymology , Humans , Male , Middle Aged , Oxidative Stress , Prospective Studies , Radiation Injuries/enzymology , Superoxide Dismutase/metabolism , Treatment Outcome
3.
Int J Clin Pract ; 58(5): 530-2, 2004 May.
Article in English | MEDLINE | ID: mdl-15206514

ABSTRACT

Henna is a traditional cosmetic agent and is used worldwide. It is used worldwide not only as a cosmetic agent to stain the hair, skin and nails but also is applied to the body on lesions in the treatment of seborrheic dermatitis or fungal infections. Different pathologies have been described as caused by henna. The aim of this study is to draw attention to the adverse effects of henna, applied over the whole body, observed in glucose-6-phosphate dehydrogenase (G6PD) enzyme deficient siblings. In the present paper, we report on two siblings with G6PD deficiency who developed haemolytic anaemia following topical application of henna to their whole body to treat skin lesions. Their parents were also found to be G6PD deficient. Even though anti-inflammatory, analgesic and antipyretic effects of henna have been shown, it may cause severe side-effects in some cases. For this reason, especially, in the regions where G6PD enzyme deficiency is common, people should be informed about the side-effects of topical henna application and clinicians should be aware of these manifestations.


Subject(s)
Anemia, Hemolytic/chemically induced , Dermatologic Agents/adverse effects , Glucosephosphate Dehydrogenase Deficiency/complications , Naphthoquinones/adverse effects , Administration, Topical , Child , Dermatologic Agents/administration & dosage , Female , Humans , Ichthyosis Vulgaris/drug therapy , Male , Naphthoquinones/administration & dosage , Pedigree , Siblings
4.
J Int Med Res ; 31(4): 253-66, 2003.
Article in English | MEDLINE | ID: mdl-12964500

ABSTRACT

We aimed to investigate the effect of zinc supplementation on oropharyngeal infections in immunocompromised patients. Thirty patients receiving radiotherapy for head and neck cancer received 150 mg/day zinc or placebo, orally, during radiotherapy and for a further 6 weeks. None received antibiotics during this period. Oropharyngeal samples were collected 1 day before the first course and 1 day after the last course of radiotherapy, and 1 week and 6 weeks after radiotherapy. Samples were cultured and pathogens identified using microbial diagnostic and gas chromatography methods. Coagulase-positive and -negative staphylococci, group A beta-haemolytic streptococci, Streptococcus pneumoniae, and Candida species were detected in both groups, but some infections, especially with Candida species and staphylococci, were prevented by zinc supplementation. We therefore suggest use of low-dose antibiotics and oral zinc supplementation in patients with these infections. No effects of zinc supplementation were observed on group A beta-haemolytic streptococci and Streptococcus pneumoniae, making it essential to start antimicrobial chemotherapy before radiotherapy.


Subject(s)
Anti-Infective Agents/therapeutic use , Bacterial Infections/drug therapy , Head and Neck Neoplasms/radiotherapy , Mycoses/drug therapy , Oropharynx/microbiology , Zinc/administration & dosage , Adolescent , Adult , Aged , Dietary Supplements , Female , Humans , Male , Middle Aged , Placebos , Prospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...